Haemodynamic evaluation of pulmonary hypertension

European Respiratory Journal

Volumn 20, Issue 5, 2002, Pages 1314-1331

  Chemia, D ^a   Castelain, V ^a   Herve P ^a   Lecarpentier, Y ^a   Brimioulle, S ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Cor pulmonale; Pulmonary hypertension; Pulmonary vasodilatory reserve; Right atrial pressure; Right ventricle; Walk test

Indexed keywords

NATRIURETIC FACTOR; VASODILATOR AGENT;

ARTERY CATHETER; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; EVALUATION; EXERCISE; FOLLOW UP; HEART DISEASE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MEASUREMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; VASODILATATION;

BLOOD PRESSURE; CATHETERIZATION, SWAN-GANZ; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; HEART CATHETERIZATION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; PULMONARY CIRCULATION; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 0036850151     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00068002     Document Type: Article

References (141)

1. Rich S. Executive summary from the world symposium on primary pulmonary hypertension 1998. Evian, France, September 6-10, 1998, co-sponsored by the World Health Organization. www.who.int/ncd/cvd/pph.html. Date updated: June 2002.
2. Weir EK, Michelakis ED, Archer SL, Rubin LJ. Pulmonary hypertension. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine. 2nd edn. Philadelphia, Churchill Livingstone, 2000; pp. 1856-1884.
3. Smiley I, Rich S, McLaughlin VV, eds. Clinics in Chest Medicine. Philadelphia, WB Saunders Company, 2001; pp. 385-595.
4. Reeves JT, Groves BM. Approach to patient with pulmonary hypertension. In: Weir EK, Reeves JT, eds. Pulmonary hypertension. Mount Kisco, NY, Futura, 1984; pp. 1-44.
5. Moraes D, Loscalzo J. Pulmonary hypertension: newer concepts in diagnosis and management. Clin Cardiol 1997; 20: 676-682.
6. Rich S, Braunwald E, Grossman W. Pulmonary hypertension. In: Braunwald E, ed. Heart disease. A Textbook of Cardiovascular Medicine. 5th edn. Philadelphia, WB Saunders Company, 1997; pp. 780-806.
7. Rich S, Dantzker DR, Ayres S, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
8. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
9. Humbert M, Trembath RC. Genetics of pulmonary hypertension: from bench to bedside. Eur Respir J 2002; 20: 741-749.
10. Milnor WR. Hemodynamics. Baltimore, William & Wilkins. 1982; pp. 1-390.
11. Fishman AP. Handbook of Physiology. Bethesda, MD, American Physiological Society, 1985; pp. 92-166.
12. Wood P. Diseases of the heart and circulation. London, Eyre and Spottiswoode, 1962.
13. McGregor M, Sniderman A. On pulmonary vascular resistance: the need for more precise definition. Am J Cardiol 1985; 55: 217-221.
14. Keller CA, Shepard JW, Chun DS, Vasquez P, Dolan GF. Pulmonary hypertension in chronic pulmonary disease. Multivariate analysis. Chest 1986; 920: 185-192.
15. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE, for the National Emphysema Treatment Trial (NETT) research group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314-322.
16. Kessler R, Faller M, Weitzenblum E, et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-224.
17. Dantzker DR, d'Alonzo GE, Bower JS, Popat K, Crevey BJ. Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. Am Rev Respir Dis 1984; 130: 412-416.
18. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17: 647-652.
19. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
20. Rubin LJ, Badesh DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
21. Hervé P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. In: Smiley I, Rich S, McLaughlin VV, eds. Clinics in Chest Medicine: Pulmonary Hypertension. Philadelphia, WB Saunders Company, 2001; pp. 451-458.
22. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to haemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581-1585.
23. Smiley I, Rich S, McLaughlin VV, eds. Cardiology Clinics: The Right Ventricle. Philadelphia, WB Saunders Company, 1992; 10: pp. 1-196.
24. Schulman DS, Matthay RA. The right ventricle in pulmonary disease. In: Smiley I, Rich S, McLaughlin VV, eds. Cardiology Clinics: The Right Ventricle. Philadelphia, WB Saunders Company, 1992; pp. 111-135.
25. Horan L, Flowers N, Havelda C. Relation between right ventricular mass and cavity size: an analysis of 1500 human hearts. Circulation 1981; 64: 135-138.
26. Wiedemann HP, Matthay RA. Cor pulmonale. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. 5th edn. Philadelphia. WB Saunders company, 1997; pp. 1604-1625.
27. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease (Part one). Am J Respir Crit Care Med 1994; 150: 833-852.
28. Brent BN, Berger HJ, Matthay RA, Mahler D, Pytlik L, Zaret BL. Physiologic correlates of right ventricular ejection fraction in chronic obstructive pulmonary disease: a combined radionuclide and hemodynamic study. Am J Cordial 1982; 5: 255-262.
29. Maddahi J, Berman D, Matsuoka D, Waxman A, Forrester J, Swan H. Right ventricular ejection fraction during exercise in normal subjects and in coronary artery disease patients: assessment by multiple-gated equilibrium scintigraphy. Circulation 1980; 62: 133-140.
30. Morrison D, Sorensen S, Caldwell J, et al. The normal right ventricular response to supine exercise. Chest 1982; 82: 686-691.
31. Weitzenblum E, Chaouat A. Right ventricular function in COPD. Can it be assessed reliably by the measurement of right ventricular ejection fraction? Chest 1998; 113: 587-589.
32. Louie EK, Rich S, Levitsky S, Brundage BH. Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. J Am Coll Cardiol 1992; 19: 84-90.
33. Nootens M, Wolfkiel CJ, Chomka EV, Rich S. Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. Am J Cardiol 1995; 75: 374-377.
34. Dhainaut JFA, Doise JM, Brunet F. Heart-lung interaction in chronic obstructive pulmonary disease. In: Derenne JP, Whitelaw WA, Similowski T, eds. Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease. New York, Marcel Dekker Inc., 1996; pp. 267-302.
35. Fishman A. Chronic cor pulmonale. Am Rev Respir Dis 1976; 114: 775-794.
36. Richens JM, Howard P. Oedema in cor pulmonale. Clin Sci 1982; 62: 255-259.
37. Stobierska B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38: 923-931.
38. Janicki JS, Weber KT, Likoff MJ, Fishman AP. The pressure-flow response of the pulmonary circulation in patients with heart failure and pulmonary vascular disease. Circulation 1985; 72: 1270-1278.
39. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
40. d'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
41. Rhodes J, Barst RJ, Garofano RP, Thoele DG, Gersony WM. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991; 18: 1738-1744.
42. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104: 429-435.
43. Laskey WK, Ferrari VA, Palevsky HI, Kussmaul WG. Pulmonary artery hemodynamics in primary pulmonary hypertension. J Am Coll Cardiol 1993; 21: 406-412.
44. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
45. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997; 95: 1479-1486.
46. di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25: 1143-1153.
47. Davidson CJ, Fishman RF, Bonow RO. Cardiac catheterization. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. 5th edn. Philadelphia, WB Saunders Company, 1997; pp. 177-203.
48. Kern MJ. Hemodynamic data. In: Kern MJ, ed. The Cardiac Catheterization Handbook. 3rd edn. St Louis, Mosby, 1999; pp. 123-223.
49. Tartulier M, Bourret M, Deyrieux F. Pulmonary arterial pressures in normal subjects. Effects of age and muscular exercise. Bull Physiopathol Respir 1972; 8: 1295-1321.
50. Ehrsam RE, Perruchoud A, Oberholzer M, Bukart F, Herzog H. Influence of age on pulmonary haemodynamics at rest and during supine exercise. Clin Sci 1983; 65: 653-660.
51. Fowler NO. The normal pulmonary arterial pressureflow relationships during exercise. Am J Med 1969; 47: 1-2.
52. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure. The role of the endothelium in pathophysiology and management. Circulation 2000; 102: 1718-1723.
53. Kafi SA, Mélot C, Vachiéry JL, Brimioulle S, Naeije R. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Coll Cardiol 1998; 31: 1372-1376.
54. Zidulka A, Hakim TS. Wedge pressure in large vs small pulmonary arteries to detect pulmonary venoconstriction. J Appl Physiol 1985; 59: 1329-1332.
55. Krokwa MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemnas. Hepatology 1997; 25: 1282-1284.
56. Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112: 980-986.
57. Hervé P, Sztrymf B, Sitbon O. Pulmonary hypertension associated with portal hypertension. In: Peacock AJ, Rubin L, eds. Pulmonary Circulation. 2nd edn. London, Edward Arnold publishers, 2002 (in press).
58. Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535-541.
59. Nootens MT, Berarducci LA, Kaufmann E, Devries S, Rich S. The prevalence and significance of a patent foramen ovale in pulmonary hypertension. Chest 1993; 104: 1673-1675.
60. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733-1744.
61. Higgenbottam T, Butt AY, Westerbeck R, Sharples L. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155.
62. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
63. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
64. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-492.
65. Wensel R, Optiz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary testing. Circulation 2002; 106: 319-324.
66. Stein P, Sabbah H, Anbe D, Marzilli M. Performance of the failing and nonfailing right ventricle of patients with pulmonary hypertension. Am J Cardiol 1979; 44: 1050-1055.
67. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-1472.
68. Archer S, Rich S. Primary pulmonary hypertension. A vascular biology and translational research "work in progress". Circulation 2000; 100: 2781-2791.
69. Rapp AH, Lange RA, Cigarroa JE, Keeley EC, Hillis LD. Relation of pulmonary arterial diastolic and mean pulmonary arterial wedge pressure in patients with and without pulmonary hypertension. Am J Cardiol 2001; 88: 823-824.
70. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973.
71. Naeije R, Vachiéry JL. Medical therapy of pulmonary hypertension. Conventional therapies. In: Smiley I, Rich S, McLaughlin VV, eds. Pulmonary hypertension. Clinics in Chest Medicine. Philadelphia, WB Saunders Company, 2001; pp. 517-527.
72. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwor J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-1174.
73. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health registry on primary pulmonary hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
74. Barst RJ, Rubin U, Long WA, et al. A comparison of continuous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
75. Sitbon O, Humbert M, Jagot JL, et al, Inhaled nitric oxide as a screening agent for sagely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.
76. Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000; 36: 2204-2211.
77. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986; 134: 342-346.
78. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990; 82: 2018-2026.
79. Robbins IM, Barst RJ, Rubin LJ. Pulmonary vasoreactivity in PPH. J Am Coll Cardiol 2001; 28: 1267-1268.
80. Rich S, Brundage B, Levy P. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985; 71: 1191-1196.
81. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488.
82. Rich S, Kaufmann E, Levy PS. The effects of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
83. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension. A safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32: 1068-1073.
84. Cope DK, Allison RC, Parmentier JL, Miller JN, Taylor AE. Measurement of effective pulmonary capillary wedge pressure using the pressure profile after pulmonary artery occlusion. Crit Care Med 1986; 14: 16-22.
85. Grimbert FA. Effective pulmonary capillary pressure. Eur Respir J 1988; 1: 297-301.
86. Naeije R, Lipski A, Abramowicz M, et al. Nature of pulmonary hypertension in congestive heart failure. Effects of cardiac transplantation. Am J Respir Crit Care Med 1994; 149: 881-887.
87. Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 338-340.
88. Fesler P, Pagnamenta A, Vachiéry JL, et al. Elevated pulmonary capillary pressure in pulmonary arterial hypertension. Eur Respir J 2002 (in press).
89. Pagnamenta A, Fesler P, Vandinivit A, Brimioulle S, Naeije R. The pulmonary vascular effects of dobutamine in experimental pulmonary hypertension. Crit Care Med 2002 (in press).
90. Brimioulle S, de Cannière D, Vachiéry JL, Antoine M, Naeije R, Le Clerc JL. Pulmonary vascular impedance predicting right ventricular failure after heart transplantation. Intensive Care Med 1997; 23: S78.
91. Castelain V, Hervé P, Lecarpentier Y, Duroux P, Simonneau G, Chemla D. Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 2001; 37: 1085-1092.
92. Chemla D, Castelain V, Simonneau G, Lecarpentier Y, Hervé P. Pulse wave reflection in pulmonary hypertension. J Am Coll Cardiol 2002; 39: 743.
93. Nakayama Y, Nakanishi N, Sugimachi M, et al. Characteristics of pulmonary artery pressure waveform for differential diagnosis of chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 1997; 29: 1311-1316.
94. Sadeghi HM, Keramati S, Sawhney N, et al. Chronic thromboembolic pulmonary hypertension and primary pulmonary hypertension: a comparison of invasive hemodynamic data. Circulation 2000; 102: Suppl. II, 716.
95. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 2797-2802.
96. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 1999; 33: 1662-1666.
97. Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant 2001; 20: 833-839.
98. Berger M, Haimowitz A, van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6: 359-365.
99. Chow LC, Dittrich HC, Hoit BD, Moser KM, Nicol PH. Doppler assessment of changes in right-sided cardiac hemodynamics after pulmonary thrombo-endarteriectomy. Am J Cardiol 1988; 61: 1092-1097.
100. Tramarin R, Torbicki B, Marchandise B, Laaban JP, Morpugi M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic pulmonary obstructive disease. A European multicentre study. Working group on non-invasive evaluation of pulmonary artery pressure. European office of the WHO, Copenhagen. Eur Heart J 1991; 12: 103-111.
101. Brecker SJ, Gibbs JS, Fox KM, Yacoub MH, Gibson DG. Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. Br Heart J 1994; 72: 384-389.
102. Masuyama T, Kodama K, Kitakabe A, Sato H, Nanto H, Inoue M. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation 1986; 74: 484-492.
103. Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol 1987; 9: 549-554.
104. Kitakabe A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983; 68: 302-309.
105. Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995; 8: 1445-1449.
106. Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987; 59: 662-668.
107. Torbicki A, Skwarski K, Hawrylkiewicz I, Pasierski T, Miskiewicz Z, Zielinski J. Attempts at measuring pulmonary arterial pressure by means of Doppler echocardiography in patients with chronic lung disease. Eur Respir J 1989; 2: 856-860.
108. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990; 15: 493-496.
109. Lavine SJ. Noninvasive estimation of right-sided pressures from spectral Doppler recordings of tricuspid and pulmonic regurgitant velocities. Chest 1999; 116: 1-3.
110. Nageh MF, Kopelen HA, Zoghbi WA, Quinones MA, Nagueh SF. Estimation of mean right atrial pressure using tissue Doppler imaging. Am J Cardiol 1999; 84: 1448-1451.
111. Jardin F, Dubourg O, Bourdarias JP. Echocardiographic pattern of cor pulmonale. Chest 1997; 111: 209-217.
112. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996; 9: 838-847.
113. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81: 1157-1161.
114. Moustapha A, Lim M, Saikia S, Kaushik V, Kang SH, Barasch E. Interrogation of the tricuspid annulus by Doppler tissue imaging in patients with chronic pulmonary hypertension: implications for the assessment of right-ventricular systolic and diastolic function. Cardiology 2001; 95: 101-104.
115. Nagaya N, Satoh T, Uematsu M, et al. Shortening of Doppler-derived deceleration time of early diastolic transmitral flow in the presence of pulmonary hypertension through ventricular interaction. Am J Cardiol 1997; 79: 1502-1506.
116. Mahmud E, Raisinghani A, Hassankhani A, et al. Correlation of left ventricular diastolic filling characteristics with right ventricular overload and pulmonary artery pressure in chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2002; 40: 318-324.
117. Krüger S, Haage P, Hoffmann R, et al. Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography. Chest 2001; 120: 1556-1561.
118. Kuriyama K, Gamsu G, Stern RG, Cann CE, Herfkens RJ, Brundage BH. CT-determined pulmonary artery diameters in predicting pulmonary hypertension. Invest Radiol 1984; 19: 16-22.
119. Tardivon AA, Mousseaux E, Brenot F, et al. Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging. Am J Respir Crit Care Med 1994; 150: 1075-1080.
120. Bergin CJ, Hauschildt J, Rios G, Belezzuoli EV, Huynh T, Channick RN. Accuracy of MR angiography compared with radionuclide scanning in identifying the cause of pulmonary arterial hypertension. Am J Roentgenol 1997; 168: 1549-1555.
121. Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary hypertension in the United States. Adult population estimates obtained from measurements of chest roentgenograms from the NHANES II survey. Chest 1989; 96: 236-241.
122. Fukuchi K, Hayashida K, Nakanishi N, et al. Quantitative analysis of lung perfusion in patients with primary pulmonary hypertension. J Nucl Med 2002; 43: 757-761.
123. Gomez A, Bialostozky D, Zajarias A, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 2001; 38: 1137-1142.
124. Gayed I, Boccalandro F, Fang B, Podoloff D. New method for calculating right ventricular ejection fraction using gated myocardial perfusion studies. Clin Nucl Med 2002; 27: 334-338.
125. Bossone E, Paciocco G, Larussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002; 121: 513-518.
126. Adnot S, Chabrier PE, Andrivet P, et al. Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension. Am Rev Respir Dis 1987; 136: 951-956.
127. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
128. Wiedmann R, Ghofrani HA, Weismann N, et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. Response to Iloprost inhalation. J Am Coll Cardiol 2001; 38: 1130-1136.
129. Rich S, Levy P. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. Am J Med 1984; 76: 573-578.
130. Glanville AR, Burke CM, Robin TJ. Primary pulmonary hypertension. length of survival in patients referred for heart-lung transplantation. Chest 1987; 91: 675-681.
131. Kanemoto N. Natural history of pulmonary hemodynamics in primary pulmonary hypertension. Am Heart J 1987; 114: 407-413.
132. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984; 70: 580-587.
133. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989; 80: 353-360.
134. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-1219.
135. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusions in primary pulmonary hypertension. Prognostic factors of survival. J Am Coll Cardiol 2002; 40: 780-788.
136. Oswald-Mammoser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
137. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158-164.
138. Hopkins WE, Ochoa LL, Richardson GW, Trulowk EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100-105.
139. Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89: 34-38.
140. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183-188.
141. Cappola TP, Felker M, Kao WHL, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy. Patients with myocarditis are a higher risk. Circulation 2002; 105: 1663-1668.